Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...

Slowed fibrosis progression comparable to that achieved with GLP-1/GIP receptor agonist or FGF-21 analogue controls, supported by statistically significant reductions in hepatic collagen staining and ...

Bariatric surgery and GLP-1s conferred similar outcomes in mortality, adverse cardiovascular events and cirrhosis development ...

Lacking awareness of metabolic dysfunction-associated steatohepatitis (MASH) constitutes a critical barrier for enhancing patient care, said Naim Alkhouri, MD. Awareness efforts can not only increase ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Researchers at Peking University have discovered that a filamentous gut fungus, Fusarium foetens, can reverse metabolic ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Semaglutide, the blockbuster drug better known by brand names like Ozempic and Wegovy, has now shown significant promise in ...

How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Key outcomes of all-cause mortality and portal hypertension complications are improved with SGLT2inhibitors, new research ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...